BLCM News and Press, Bellicum Pharmaceuticals Inc. From 11/10/22

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. “We are enc...

HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be ...

HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investmen...

Bellicum Pharmaceuticals press release ( NASDAQ: BLCM ): Q2 GAAP EPS of -$0.13 beats by $0.56 . Cash and cash equivalents and restricted cash totaling $34.7M as of June 30, 2022. “We have continued to make progress with our patient enrollment efforts in the ...

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update. “We have c...

Bellicum Pharmaceuticals press release (NASDAQ:BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42. Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March 31, 2022, compared to $47.7 million as of December 31, 2021. For further details see: Bellicum P...

HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update. “I am please...

Shares of Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) traded at a new 52-week high today of $23.11. This new high was reached on above average trading volume as 67.8 million shares traded hands, while the average 30-day volume is approximately 34,000 shares. Bellicum Pharmaceuticals Inc ...

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid tumors - - Previously re...

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Con...